Skip to Content

Analysts have raised their earnings per share estimates for Genmab A/S (NASDAQ:GMAB) for fiscal year 2022.

Analysts have raised their earnings per share estimates for Genmab A/S (NASDAQ:GMAB) for fiscal year 2022.

The headquarters of the pharmaceutical company Genmab A/S, which trades on the NASDAQ under the symbol GMAB, are located in the Danish capital of Copenhagen. HC Wainwright equity analysts, in a research note that was distributed to investors on Tuesday, January 3, 2019, raised their projections for the earnings per share of Genmab A/FY2022 S. R. Selvaraju, an analyst who works for HC Wainwright, has increased his previous estimate of the company’s profits per share for this year, bringing it up to $1.36 from the previous figure of $1.28. This brings R. Selvaraju’s full-year earnings per share forecast for the company to $1.36. The most recent average estimate places Genmab A’s and full-year S’s earnings at $1.33 per share, which is the amount that is anticipated to be earned by the company. In addition, HC Wainwright has projected that Genmab A/Q4 S will bring in earnings of $0.30 per share in 2022, $0.10 per share in 2023, $0.18 per share in 2023, and $0.76 per share in 2023.
On Friday, shares of NASDAQ: GMAB started trading for $42.12 per unit. The company’s moving average price over the past 50 days is $43.19, and its average price over the past 200 days is $37.84. During the previous year, the price of Genmab A/S fluctuated between $26.19 and $47.50, with a low of $26.19 and a high of $47.50, respectively. The stock has a price-to-earnings-growth ratio of 1.20, a price-to-earnings ratio of 34.52, and a beta value of 1.02. The market capitalization of the company is $27.78 billion.
The stock these equity analysts have been following has also been the subject of research reports published by other equity analysts. JPMorgan Chase & Co. increased their price objective on shares of Genmab A/S from $3,450.00 to $3,600.00 and rated the company “overweight” in a report published on Tuesday. In a research note published on November 14, William Blair announced that the firm would soon begin covering shares of Genmab A/S. They gave the stock a rating of “market perform” for its performance. The “sell” rating that AlphaValue assigned to shares of Genmab A/S in their research report published on November 17 increased from the “hold” rating they had previously assigned to those same shares. Genmab A/S went from having a “buy” rating to having a “hold” rating in a research report that Deutsche Bank Aktiengesellschaft published on November 11. As a result of this change, the company’s recommendation for Genmab A/S was changed. The “buy” rating that Citigroup had previously assigned to Genmab A/S was downgraded to a “neutral” rating in a research note published on December 20. The final and most significant adjustment was made here. Three professionals working in the financial industry have recommended buying the stock, ten others have stated that it should be held, and two equity research analysts have stated that it should be sold. According to, the current recommendation for Genmab A/S is “Hold,” The website also reports that market analysts anticipate the company’s stock will reach an average price of $632.12 per share.
In recent months, several hedge funds and institutional investors have either increased the percentage of GMAB stock they are currently holding or decreased the amount of money they have invested in the company. Private Advisor Group LLC increased its holdings of Genmab A/S stock by 2.0% over the second quarter. Private Advisor Group LLC currently holds an ownership interest in 20,522 shares. The value of these shares is $666,000. During the most recent quarter, this represented an increase in ownership equivalent to 403 additional shares. During the second quarter of 2018, Franklin Resources Inc. increased its holdings in Genmab A/S by a percentage equivalent to 52 percent. Franklin Resources Inc. has increased its holdings to a total value of $318,000 by purchasing 3,342 additional shares of the company’s stock since the beginning of this fiscal quarter. During the second quarter of the fiscal year, Clal Insurance Enterprises Holdings Ltd. increased the percentage of Genmab A/S shares it owned by 62.0%. The most recent quarter saw Clal Insurance Enterprises Holdings Ltd acquire an additional 18,600 shares of the company’s stock, bringing the total number of shares it owns to 48,600, with a value of $1,579,000. This brings the total number of shares it has in the business to 48,600. The value of NewEdge Wealth LLC’s holdings of Genmab A/S stock increased by 359.7% during the second quarter compared to the previous quarter’s value. As a direct result of NewEdge Wealth LLC’s recent successful completion of the purchase of an additional 20,392 shares, the company now directly owns 26,061 shares, which have a value of $847,000. And finally, but certainly not least, during the second quarter, Vestmark Advisory Solutions Inc. expanded its holdings in Genmab A/S by increasing the number of shares it owned by 80.0%. Vestmark Advisory Solutions Inc. now has a total of 39,141 shares of the company’s stock, which are worth a total of $1,272,000 after purchasing an additional 17,394 shares during the most recent quarter. Institutional investors hold a total of 6.73 percent of the company’s outstanding shares, making up the total of this percentage.
Genmab A/S is a company with its headquarters in Denmark that specializes in producing antibody treatments for various diseases, including cancer. For example, Darzalex is a human monoclonal antibody that is used to treat multiple myeloma (MM); teprotumumab is used to treat thyroid eye disease; ofatumurnab is used to treat CLL and MS; and amivantamab is used to treat advanced or metastatic gastric or esophageal cancer as well as non-small cell lung cancer. These medications have been approved by the Food and Drug Administration (FDA) (NSCLC).


Leave a comment

Your email address will not be published. Required fields are marked *